Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yuichi Sakamori; Chiyuki Okuda; Young Hak Kim; Tadashi Mio; Michiaki Mishima

doi:10.1007/s12032-011-0009-7

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

Katsuhiro Masago, Yosuke Togashi, Shiro Fujita, Yuichi Sakamori, Chiyuki Okuda, Young Hak Kim, Tadashi Mio, Michiaki Mishima

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.

Original language	English
Pages (from-to)	1614-1621
Number of pages	8
Journal	Medical Oncology
Volume	29
Issue number	3
DOIs	https://doi.org/10.1007/s12032-011-0009-7
Publication status	Published - Sept 2012
Externally published	Yes

Keywords

Epidermal growth factor receptor
Gefitinib
Hepatocyte growth factor
Non-small cell lung cancer
Somatic mutation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12032-011-0009-7

Cite this

Masago, K., Togashi, Y., Fujita, S., Sakamori, Y., Okuda, C., Kim, Y. H., Mio, T., & Mishima, M. (2012). Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Medical Oncology, 29(3), 1614-1621. https://doi.org/10.1007/s12032-011-0009-7

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. / Masago, Katsuhiro; Togashi, Yosuke; Fujita, Shiro et al.
In: Medical Oncology, Vol. 29, No. 3, 09.2012, p. 1614-1621.

Research output: Contribution to journal › Article › peer-review

Masago, K, Togashi, Y, Fujita, S, Sakamori, Y, Okuda, C, Kim, YH, Mio, T & Mishima, M 2012, 'Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib', Medical Oncology, vol. 29, no. 3, pp. 1614-1621. https://doi.org/10.1007/s12032-011-0009-7

@article{edb1dbed2519467aa6bbbf6a19283bcb,

title = "Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib",

abstract = "A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.",

keywords = "Epidermal growth factor receptor, Gefitinib, Hepatocyte growth factor, Non-small cell lung cancer, Somatic mutation",

author = "Katsuhiro Masago and Yosuke Togashi and Shiro Fujita and Yuichi Sakamori and Chiyuki Okuda and Kim, {Young Hak} and Tadashi Mio and Michiaki Mishima",

year = "2012",

month = sep,

doi = "10.1007/s12032-011-0009-7",

language = "English",

volume = "29",

pages = "1614--1621",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

AU - Masago, Katsuhiro

AU - Togashi, Yosuke

AU - Fujita, Shiro

AU - Sakamori, Yuichi

AU - Okuda, Chiyuki

AU - Kim, Young Hak

AU - Mio, Tadashi

AU - Mishima, Michiaki

PY - 2012/9

Y1 - 2012/9

N2 - A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.

AB - A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.

KW - Epidermal growth factor receptor

KW - Gefitinib

KW - Hepatocyte growth factor

KW - Non-small cell lung cancer

KW - Somatic mutation

UR - http://www.scopus.com/inward/record.url?scp=84872801006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872801006&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-0009-7

DO - 10.1007/s12032-011-0009-7

M3 - Article

C2 - 21779929

AN - SCOPUS:84872801006

SN - 1357-0560

VL - 29

SP - 1614

EP - 1621

JO - Medical Oncology

JF - Medical Oncology

IS - 3

ER -

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this